Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 3.2% - Here's Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price shot up 3.2% on Tuesday . The stock traded as high as $5.70 and last traded at $5.59. 3,312,550 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 12,046,141 shares. The stock had previously closed at $5.41.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Morgan Stanley dropped their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $8.20.

Recursion Pharmaceuticals Stock Up 0.5 %

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.32 billion, a PE ratio of -3.79 and a beta of 1.00. The business has a fifty day moving average of $6.31 and a 200 day moving average of $6.78.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business's revenue was down 57.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.42) EPS. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the company. PDS Planning Inc acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth $69,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $67,000. Cambridge Investment Research Advisors Inc. boosted its holdings in Recursion Pharmaceuticals by 33.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 117,120 shares of the company's stock valued at $620,000 after purchasing an additional 29,136 shares in the last quarter. San Luis Wealth Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter worth approximately $54,000. Finally, QRG Capital Management Inc. lifted its position in shares of Recursion Pharmaceuticals by 8.5% during the 1st quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock worth $151,000 after buying an additional 2,244 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.